Immediate early response 3 promotes airway epithelial inflammation and represents a therapeutic target in chronic obstructive pulmonary disease
Abstract
BackgroundChronic obstructive pulmonary disease (COPD) is characterized by persistent airway inflammation, yet clinically useful biomarkers and mechanistically validated therapeutic targets remain limited. Here, we aimed to identify and functionally validate smoke-responsive regulators of airway epithelial inflammation in COPD and establish an interpretable prediction framework by integrating population-based clinical data, multi-omics analyses, genetic causal inference, and experimental validation.MethodsComplementary clinical and molecular investigations used separate populations. Interpretable machine-learning models classified recorded COPD status in CHARLS, with validation across survey waves. Independent lung transcriptomic analyses integrated differential expression, co-expression networks, 113 machine-learning configurations, and single-cell profiling. Two-sample Mendelian randomization examined genetically predicted IER3 expression in relation to FEV1/FVC. Functional effects of IER3 were evaluated through AAV-mediated silencing in cigarette-smoke–exposed mice and siRNA knockdown in cigarette-smoke-extract–stimulated bronchial epithelial cells. Drug screening and molecular simulations prioritized candidate compounds for further investigation.ResultsThe support vector machine achieved the best predictive performance for COPD risk (test AUC = 0.821; temporal validation AUC = 0.829). Multi-omics analyses consistently identified IER3 as a central COPD-associated gene within an inflammation-enriched transcriptional network. A six-gene diagnostic signature demonstrated robust external performance (AUC = 0.882 and 0.836), with IER3 and ATF3 emerging as the most reproducible biomarkers across independent cohorts. Single-cell analysis localized IER3 predominantly to airway epithelial cells and macrophages and revealed enhanced epithelial–macrophage communication in COPD. Mendelian randomization supported a causal association between genetically predicted IER3 expression and impaired lung function (IVW β = −0.042, P < 0.001). Experimental studies further demonstrated that cigarette smoke induced epithelial IER3 expression, whereas IER3 silencing suppressed pro-inflammatory cytokine production, reduced inflammatory-cell recruitment, alleviated lung injury, and partially restored pulmonary function. Drug-repurposing analysis nominated IMD-0354 as a potential candidate modulator of the IER3-associated inflammatory axis.ConclusionsWe developed an interpretable machine-learning framework for COPD risk prediction and identified IER3 as a candidate mediator of airway epithelial inflammation. Integrated evidence supports its involvement in smoke-induced inflammatory amplification and potential contribution to impaired lung function, highlighting IER3 as a potential therapeutic target warranting further mechanistic and clinical validation.
Related
- CD47 fuels intestinal fibrosis by inducing fibroblast phagocytic evasion and represents a therapeutic target
- Sense-and-respond: Engineered bacteria drive epithelial repair during gut inflammation
- SETD3 ACTIN HISTIDINE METHYLTRANSFERASE REGULATES INTESTINAL EPITHELIAL BARRIER INTEGRITY AND MUCOSAL INFLAMMATION
- Identification of a Novel Inhibitor of Human Rhinovirus Replication and Inflammation in Airway Epithelial Cells
- Anorectal care products cause variable inflammation and adverse barrier effects in a mucosal epithelial model
BibTeX
@article{yang2026immediate,
title = {{Immediate early response 3 promotes airway epithelial inflammation and represents a therapeutic target in chronic obstructive pulmonary disease}},
author = {Yuanlan Yang and Zhengyu Hu and Wenjing Wang and Mindan Wu and Yachao Cui and Zemin Chen and Xuan Jin and Wenfeng Huang and Jiawei Yan and Feng Zhang and Wenguang Yin and Jieda Cui and Leqing Zhu and Pixin Ran and Jianwei Dai},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1952064},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1952064},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immediate early response 3 promotes airway epithelial inflammation and represents a therapeutic target in chronic obstructive pulmonary disease
AU - Yuanlan Yang
AU - Zhengyu Hu
AU - Wenjing Wang
AU - Mindan Wu
AU - Yachao Cui
AU - Zemin Chen
AU - Xuan Jin
AU - Wenfeng Huang
AU - Jiawei Yan
AU - Feng Zhang
AU - Wenguang Yin
AU - Jieda Cui
AU - Leqing Zhu
AU - Pixin Ran
AU - Jianwei Dai
PY - 2026
DA - 2026/11/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1952064
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1952064
AB - BackgroundChronic obstructive pulmonary disease (COPD) is characterized by persistent airway inflammation, yet clinically useful biomarkers and mechanistically validated therapeutic targets remain limited. Here, we aimed to identify and functionally validate smoke-responsive regulators of airway epithelial inflammation in COPD and establish an interpretable prediction framework by integrating population-based clinical data, multi-omics analyses, genetic causal inference, and experimental validation.MethodsComplementary clinical and molecular investigations used separate populations. Interpretable machine-learning models classified recorded COPD status in CHARLS, with validation across survey waves. Independent lung transcriptomic analyses integrated differential expression, co-expression networks, 113 machine-learning configurations, and single-cell profiling. Two-sample Mendelian randomization examined genetically predicted IER3 expression in relation to FEV1/FVC. Functional effects of IER3 were evaluated through AAV-mediated silencing in cigarette-smoke–exposed mice and siRNA knockdown in cigarette-smoke-extract–stimulated bronchial epithelial cells. Drug screening and molecular simulations prioritized candidate compounds for further investigation.ResultsThe support vector machine achieved the best predictive performance for COPD risk (test AUC = 0.821; temporal validation AUC = 0.829). Multi-omics analyses consistently identified IER3 as a central COPD-associated gene within an inflammation-enriched transcriptional network. A six-gene diagnostic signature demonstrated robust external performance (AUC = 0.882 and 0.836), with IER3 and ATF3 emerging as the most reproducible biomarkers across independent cohorts. Single-cell analysis localized IER3 predominantly to airway epithelial cells and macrophages and revealed enhanced epithelial–macrophage communication in COPD. Mendelian randomization supported a causal association between genetically predicted IER3 expression and impaired lung function (IVW β = −0.042, P < 0.001). Experimental studies further demonstrated that cigarette smoke induced epithelial IER3 expression, whereas IER3 silencing suppressed pro-inflammatory cytokine production, reduced inflammatory-cell recruitment, alleviated lung injury, and partially restored pulmonary function. Drug-repurposing analysis nominated IMD-0354 as a potential candidate modulator of the IER3-associated inflammatory axis.ConclusionsWe developed an interpretable machine-learning framework for COPD risk prediction and identified IER3 as a candidate mediator of airway epithelial inflammation. Integrated evidence supports its involvement in smoke-induced inflammatory amplification and potential contribution to impaired lung function, highlighting IER3 as a potential therapeutic target warranting further mechanistic and clinical validation.
SN - 1664-3224
ER -